| Title | Phase I/II Study of Concurrent Chemoradiotherapy for Localized Nasal Natural Killer/T-Cell Lymphoma: Japan Clinical Oncology Group Study JCOG0211. | | Author(s) | Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, Ishizawa K, Maseki N, Itoh K, Usui N, Wasada I, Kinoshita T, Ohshima K, Matsuno Y, Terauchi T, Nawano S, Ishikura S, Kagami Y, Hotta T, Oshimi K | | Institution | Department of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu; Hematology and Stem Cell Transplantation Division and the Radiation Oncology Division, National Cancer Center Hospital; Department of Radiation Oncology, Japanese Foundation for Cancer Research Cancer Institute Hospital; Department of Community Health and Medicine, Research Institute International Medical Center of Japan; Department of Hematology, Juntendo University School of Medicine; Division of Hematology and Oncology, Jikei University School of Medicine; Screening Technology and Development Division, Research Center for Cancer Prevention and Screening, National Cancer Center; Center for Radiological Sciences, International University of Health and Welfare Mita Hospital; Clinical Trials and Practice Support Division, Center for Cancer Control and Information Services, National Cancer Center, Tokyo; Department of Hematology & Rheumatology, Tohoku University Hospital, Sendai; Department of Hematology, Saitama Cancer Center, Ina; Division of Hematology and Oncology, National Cancer Center Hospital East, Kashiwa; Department of Hematology, Tokai University, Isehara; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine; Department of Internal Medicine, National Hospital Organization Nagoya Medical Center, Nagoya; Department of Pathology, Kurume University School of Medicine, Kurume; and the Department of Surgical Pathology, Hokkaido University Hospital, Sapporo, Japan. | | Source | J Clin Oncol 2009 Oct 5. | | Abstract | PURPOSE: To explore a more effective treatment for localized nasal natural killer (NK)/T-cell lymphoma, we conducted a phase I/II study of concurrent chemoradiotherapy.
PATIENTS AND METHODS: Treatments comprised concurrent radiotherapy (50 Gy) and 3 courses of dexamethasone, etoposide, ifosfamide, and carboplatin (DeVIC). Patients with a newly diagnosed stage IE or contiguous IIE disease with cervical node involvement and a performance status (PS) of 0 to 2 were eligible for enrollment. The primary end point of the phase II portion was a 2-year overall survival in patients treated with the recommended dose.
RESULTS: Of the 33 patients enrolled, 10 patients were enrolled in the phase I portion and a two thirds dose of DeVIC was established as the recommended dose. Twenty-seven patients (range, 21 to 68; median, 56 years) treated with the recommended dose showed the following clinical features: male:female, 17:10; stage IE, 18; stage IIE, 9; B symptoms present, 10; elevated serum lactate dehydrogenase, 5; and PS 2, 2. With a median follow-up of 32 months, the 2-year overall survival was 78% (95% CI, 57% to 89%). This compared favorably with the historical control of radiotherapy alone (45%). Of the 26 patients assessable for a response, 20 (77%) achieved a complete response, with one partial response. The overall response rate was 81%. The most common grade 3 nonhematologic toxicity was mucositis related to radiation (30%). No treatment-related deaths were observed.
CONCLUSION: Concurrent chemoradiotherapy using multidrug resistance-nonrelated agents and etoposide is a safe and effective treatment for localized nasal NK/T-cell lymphoma and warrants further investigation. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19805668 |
|
